Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

por Hanefeld, M
Publicado 2007

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes

por Pistrosch, F., Köhler, C., Schaper, F., Landgraf, W., Forst, T., Hanefeld, M.
Publicado 2013

Rosiglitazone RECORD study: glucose control outcomes at 18 months

por Home, P D, Jones, N P, Pocock, S J, Beck-Nielsen, H, Gomis, R, Hanefeld, M, Komajda, M, Curtis, P
Publicado 2007

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

por Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., Pirags, V., Scheen, A., Seufert, J., Sjohölm, A., Tsatsoulis, A., DeFronzo, R.
Publicado 2010

Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

por Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., Pirags, V., Scheen, A., Seufert, J., Sjöholm, Å., Tsatsoulis, A., DeFronzo, R.
Publicado 2010